Last quarter (Q4 2022), Clinuvel Pharmaceuticals Limited's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Clinuvel Pharmaceuticals Limited's net income was AU$―. See Clinuvel Pharmaceuticals Limited’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	-	-	AU$ 65.72M	AU$ 47.98M	AU$ 32.57M	AU$ 31.05M
Cost of Revenue	-	-	AU$ 10.48M	AU$ 4.72M	AU$ 9.63M	AU$ 6.87M
Gross Profit	-	-	AU$ 55.24M	AU$ 43.26M	AU$ 22.94M	AU$ 24.18M
Operating Expense	-	-	AU$ 19.91M	AU$ 15.03M	AU$ 11.55M	AU$ 7.49M
Operating Income	-	-	AU$ 35.33M	AU$ 28.22M	AU$ 11.39M	AU$ 16.69M
Net Non Operating Interest Income Expense	-	-	AU$ -1.83M	AU$ -1.28M	AU$ 537.04K	AU$ 543.54K
Other Income Expense	-	-	AU$ 821.15K	AU$ -1.24M	AU$ 781.32K	AU$ 880.48K
Pretax Income	-	-	AU$ 34.32M	AU$ 25.71M	AU$ 13.14M	AU$ 18.11M
Tax Provision	-	-	AU$ 13.44M	AU$ 984.40K	AU$ -3.51M	AU$ -19.33K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	-	AU$ 20.88M	AU$ 24.73M	AU$ 16.65M	AU$ 18.13M
Basic EPS	-	-	AU$ 0.42	AU$ 0.50	AU$ 0.34	AU$ 0.38
Diluted EPS	-	-	AU$ 0.40	AU$ 0.48	AU$ 0.33	AU$ 0.37
Basic Average Shares	-	-	AU$ 49.41M	AU$ 49.41M	AU$ 49.26M	AU$ 48.19M
Diluted Average Shares	-	-	AU$ 51.81M	AU$ 51.09M	AU$ 50.45M	AU$ 49.55M
Dividend Per Share	-	-	AU$ 0.03	AU$ 0.03	AU$ 0.03	AU$ 0.02
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	-	-	AU$ 20.88M	AU$ 24.73M	AU$ 16.65M	AU$ 18.13M
Normalized Income	-	-	AU$ 20.88M	AU$ 24.73M	AU$ 16.65M	AU$ 18.13M
Interest Expense	-	-	AU$ 2.27M	AU$ 1.62M	AU$ 25.89K	AU$ 21.11K
EBIT	-	-	AU$ 36.60M	AU$ 27.33M	AU$ 13.16M	AU$ 18.14M
EBITDA	-	AU$ 49.56M	AU$ 37.35M	AU$ 28.19M	AU$ 13.59M	AU$ 18.14M

Currency in AUD

Clinuvel Pharmaceuticals Limited Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing